AIM When selecting treatments for type 2 diabetes (T2D), it is important to consider not only efficacy and safety, but also other treatment attributes that have an impact on patient preference. The objective of this study was to examine preference between injection devices used for two weekly GLP-1 receptor agonists. MATERIALS AND METHODS The PREFER study was an open-label, multicentre, randomized, crossover study assessing patient preference for dulaglutide and semaglutide injection devices among injection-naïve patients receiving oral medication for type 2 diabetes. After being trained to use each device, participants performed all steps of injection preparation and administered mock injections into an injection pad. Time-to-train (TTT) for each device was assessed in a subset. RESULTS There were 310 evaluable participants (48.4% female; mean age, 60.0 years; 78 participants in the TTT subgroup). More participants preferred the dulaglutide device than the semaglutide device (84.2% vs. 12.3%; P < 0.0001). More participants perceived the dulaglutide device to have greater ease of use (86.8% vs. 6.8%; P < 0.0001). After preparing and using the devices, more participants were willing to use the dulaglutide device (93.5%) than the semaglutide device (45.8%). Training participants to use the dulaglutide device required less time than the semaglutide device (3.38 vs. 8.14 minutes; P < 0.0001). CONCLUSIONS Participants with type 2 diabetes preferred the dulaglutide injection device to the semaglutide injection device. If patients prefer a device, they may be more willing to use the medication, which could result in better health outcomes. Furthermore, a shorter training time for injection devices may be helpful in busy clinical practice settings.

中文翻译：

---

评估患者对度拉鲁肽笔和索马鲁肽笔之间的偏好：交叉研究 (PREFER)。

目的 在选择 2 型糖尿病 (T2D) 的治疗方法时，重要的是不仅要考虑疗效和安全性，还要考虑对患者偏好有影响的其他治疗属性。本研究的目的是检查用于两种每周 GLP-1 受体激动剂的注射装置之间的偏好。材料和方法 PREFER 研究是一项开放标签、多中心、随机、交叉研究，评估接受口服药物治疗 2 型糖尿病的未注射患者对度拉鲁肽和索马鲁肽注射装置的偏好。在接受了使用每种设备的培训后，参与者执行了注射准备的所有步骤，并将模拟注射剂注入注射垫。每个设备的训练时间 (TTT) 在一个子集中进行评估。结果 有 310 名可评估的参与者（48.4% 为女性；平均年龄，60.0 岁；TTT 小组中有 78 名参与者）。与索马鲁肽装置相比，更多参与者更喜欢度拉鲁肽装置（84.2% 对 12.3%；P < 0.0001）。更多参与者认为度拉鲁肽装置更易于使用（86.8% 对 6.8%；P < 0.0001）。在准备和使用设备后，愿意使用度拉鲁肽设备的参与者（93.5%）多于索马鲁肽设备（45.8%）。训练参与者使用 dulaglutide 装置比使用 semaglutide 装置所需的时间更少（3.38 分钟 vs. 8.14 分钟；P < 0.0001）。结论 患有 2 型糖尿病的参与者更喜欢度拉鲁肽注射装置而不是索马鲁肽注射装置。如果患者更喜欢设备，他们可能更愿意使用药物，这可能会带来更好的健康结果。此外，